GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Total Liabilities

Outlook Therapeutics (FRA:41O) Total Liabilities : €64.27 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Total Liabilities?

Outlook Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was €64.27 Mil.

Outlook Therapeutics's quarterly Total Liabilities declined from Jun. 2024 (€121.48 Mil) to Sep. 2024 (€91.81 Mil) and declined from Sep. 2024 (€91.81 Mil) to Dec. 2024 (€64.27 Mil).

Outlook Therapeutics's annual Total Liabilities increased from Sep. 2022 (€19.99 Mil) to Sep. 2023 (€43.79 Mil) and increased from Sep. 2023 (€43.79 Mil) to Sep. 2024 (€91.81 Mil).

Outlook Therapeutics Total Liabilities Historical Data

The historical data trend for Outlook Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Total Liabilities Chart

Outlook Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.35 15.47 19.99 43.79 91.81

Outlook Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.21 177.80 121.48 91.81 64.27

Outlook Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Outlook Therapeutics's Total Liabilities for the fiscal year that ended in Sep. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=38.341+(0.223+53.248
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=91.81

Total Liabilities=Total Assets (A: Sep. 2024 )-Total Equity (A: Sep. 2024 )
=25.97--65.842
=91.81

Outlook Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=46.066+(0.223+17.979
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=64.27

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=16.241--48.027
=64.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Total Liabilities
Comparable Companies
PEPG PRLD ICCC AVTX OKYO ARMP ACET FBIO ACRV KPTI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
OTLK:USA
Address
111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Website
https://www.outlooktherapeutics.com
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines